United Therapeutics Co. (NASDAQ:UTHR) Director Sells $797,000.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Down 0.9 %

Shares of UTHR opened at $308.02 on Friday. The stock’s 50-day moving average price is $341.10 and its 200 day moving average price is $355.98. The firm has a market capitalization of $13.83 billion, a price-to-earnings ratio of 13.53, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business posted $4.36 earnings per share. Equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on UTHR shares. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the fourth quarter worth about $25,000. Brooklyn Investment Group acquired a new stake in United Therapeutics during the third quarter valued at approximately $33,000. Dunhill Financial LLC grew its stake in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares during the period. State of Wyoming acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $62,000. Finally, Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $67,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.